The stock analysts at Truist Financial boosted their target price for AdaptHealth (NASDAQ: AHCO), raising it from $26.00 to $28.00, according to a research note that was issued on Monday. The Fly was the source from which I acquired this information. Truist Financial’s price objective represents a potential gain of 37.05 percent over the stock’s current price. In recent times, numerous research analysts from various institutions have, in their own right, conducted examinations of the organization. In a research report made public on August 10 by SVB Leerink, the company was given an “outperform” rating, and the price target set for AdaptHealth increased from $24.00 to $29.00. In addition, the price target was increased from $24.00 to $29.00.
The announcement was made by Deutsche Bank Aktiengesellschaft in a research note that was released on Wednesday, August 10, and stated that the company had increased its price objective for AdaptHealth from $22.00 to $26.00. TheStreet raised its previous evaluation of AdaptHealth’s stock from a grade of “d+” to a grade of “c-” in a research report released on August 2. The company shares have been assigned a buy rating and recommended for purchase by four separate research analysts. According to data sourced from Bloomberg.com, the consensus on the price objective for AdaptHealth is currently set at $26.83, and the average rating for the business is currently “Buy.”
When the market opened on Monday, the price of a share of AdaptHealth was $20.43 per share. The cost of AdaptHealth might be anything from $11.40 to $28.75 per month when calculated over a single year. The stock price has had a moving average of $18.00 over the previous 200 days, and it has had a price of $20.80 during the most recent 50 days. To maintain proper financial stability, the debt-to-equity ratio is kept at a value of 1.02, the quick ratio is kept at 1.15, and the current ratio is kept at 1.39. The company has a price-to-earnings ratio of 38.75, a price-to-earnings-to-growth ratio of 0.32, and a beta value of 0.59. These are all measures of how expensive its stock is relative to its earnings. The total value of the corporation, as measured by its market capitalization, is $2.74 billion.
AdaptHealth (NASDAQ: AHCO) updated its most recent quarterly financial report on August 9, when it revealed the results of the report. The firm reported earnings of $0.09 per share for the quarter, which was much lower than the consensus estimate of $0.32 per share, representing a difference of $0.23. The company reported a total of $727.61 million in sales during the quarter, which is higher than the average estimated $724.27 million in sales for the quarter. The return on equity for AdaptHealth was 6.49 percent, and the net margin for the business was 4.91 percent. The most recent fiscal quarter of the company saw sales rise by 17.9% compared to the same period in the previous year. When measured against the previous year’s performance, the value of each share of the company’s stock dropped by $0.11 overall. Most experts in the financial industry think that AdaptHealth will earn 1.37 cents per share in 2018.
On Friday, August 12, Everest Hill Group Inc., the largest shareholder in AdaptHealth, sold 215,382 shares of the company’s stock. This information was included in previous AdaptHealth news stories. Because each share was sold for an average of $23.50, the total sales volume came to $5,061,477.00. The market determined the price of the shares. The completion of the transaction has resulted in the insider now directly owning company stock with a value of $355,316,099. (15,119,834 shares). The Securities and Exchange Commission (SEC) keeps a legal file open to the public and can be read online. This file had information relevant to the transaction, which was discovered there. Related news and articles On August 12, Everest Hill Group Inc., a significant shareholder in the company, sold 215,382 shares of the company’s stock. Because each share was sold for an average of $23.50, the total sales volume came to $5,061,477.00.
The market determined the price of the shares. As a result of the acquisition, the insider’s total shareholding value has increased to 355,316,099 dollars. Following the link provided in the previous line, you will be able to examine the filing made with the Securities and Exchange Commission that made the transaction public knowledge. In addition, on August 16, the company’s general counsel, Christopher J. Joyce, sold 100,000 shares. In the market, a total of 2,220,000.00 dollars’ worth of shares were traded at an average price of $22.20 per share. The general counsel now owns 106,071 shares of the company, which have an approximate value of $2,354,776.20 as a direct result of the transaction. Disclosures that are related to the sale might be found in this section of the website. Over the previous three months, corporate insiders sold 474,382 company stock, resulting in a total profit of $10,938,477 for the business. Company insiders own 17.29% of the total shares now outstanding in the corporation.
Institutional investors recently altered the proportion of the company’s stock they owned in their respective portfolios. During the first three months of 2018, Nisa Investment Advisors LLC boosted the number of AdaptHealth shares it owned by 96.6% relative to the previous quarter. After purchasing an additional 840 shares of the company during the quarter, Nisa Investment Advisors LLC now has a total ownership stake, equal to 1,710 shares worth $27,000. This was accomplished by purchasing an additional 840 shares of the firm. In addition, Covestor Ltd. spent close to 35,000 dollars on buying a new stake in AdaptHealth during the last three months of 2018, when the company was still in 2018. During the second quarter, US Bancorp DE boosted the percentage of AdaptHealth stock owned by 121.7%. US Bancorp DE now has a total of 2,614 shares, valued at $48,000, after purchasing an additional 1,435 shares during the preceding quarter.
US Bancorp DE purchased these shares. Group One Trading L.P. increased the percentage of AdaptHealth stock owned by 134.3% during the first three months of the year. After purchasing an additional 2,132 shares over the past three months, Group One Trading L.P. now owns 3,720 shares of the company’s stock, valued at $60,000. This brings the total value of Group One Trading L.P.’s stock holdings to $60,000. Last but not least, in the previous quarter of 2016, Advisor Group Holdings Inc. boosted the amount of money it had invested in AdaptHealth by 306.5 percent. Advisor Group Holdings Inc. holds a total of 3,000 shares currently valued at $73,000. During the quarter, the company purchased an additional 2,262 shares, bringing the total number of shares purchased to 3,000. Institutional investors own most of the company’s shares, up to 75.76% of the total shares.
Customers in the United States can take advantage of the home and other connected services, medical supplies, and home medical equipment (HME) that AdaptHealth Corp. and its affiliates provide. Patients discharged from acute care and other hospitals might receive home medical equipment (HME) from Chronicall, a company that specializes in providing such products. In addition, the company can bring oxygen and other chronic therapy services directly to the patient’s home. In addition, the company can provide other HME devices and supplies. People suffering from obstructive sleep apnea can benefit from the company’s sleep therapy services, which include CPAP and bi-PAP, as well as sleep therapy equipment, supplies, and related services. Patients who have diabetes can receive medical devices and supplies from this company, including insulin pumps and continuous glucose monitors, amongst other things. After a patient leaves an acute care facility or another facility, they may also get medical equipment at home.